Navigation Links
OncoSec Medical Announces $7.2 Million Public Offering
Date:12/13/2012

SEC's website at www.sec.gov or by request at Dawson James Securities, Inc. by e-mailing placements@djsiny.com.

This announcement is neither an offer to sell nor a solicitation of an offer to buy any of OncoSec's common stock or warrants. No offer, solicitation or sale will be made in any jurisdiction in which such offer, solicitation or sale is unlawful.

About OncoSec Medical Inc.

OncoSec Medical Inc. is a biopharmaceutical company developing its advanced-stage ImmunoPulse DNA-based immunotherapy and NeoPulse therapy to treat solid tumor cancers. ImmunoPulse and NeoPulse therapies address an unmet medical need and represent a potential solution, for less invasive and less expensive therapies that are able to minimize detrimental effects resulting from currently available cancer treatments such as surgery, systemic chemotherapy or immunotherapy and other treatment alternatives.  OncoSec Medical's core technology is based upon its proprietary use of an electroporation platform to dramatically enhance the delivery and uptake of a locally delivered DNA-based immunocytokine (ImmunoPulse) or chemotherapeutic agent (NeoPulse). Treatment of various solid cancers using these powerful and targeted anti-cancer agents has demonstrated selective destruction of cancerous cells while sparing healthy normal tissues during early and late stage clinical trials. OncoSec's clinical programs include three Phase II clinical trials for ImmunoPulse targeting lethal skin cancers. More information is available at http://www.oncosec.com/.

This press release contains forward looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this release that are not historical facts may be considered such "forward looking statements." Forward looking statements are based on management's cu
'/>"/>

SOURCE OncoSec Medical Incorporated
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. OncoSec ElectroChemotherapy Demonstrates Potential as Alternative to Surgery for Treating Head and Neck Cancer
2. OncoSec Medical Issues Letter to Shareholders
3. OncoSec Presents Preliminary Safety Data for Phase II Melanoma Study at Second European Post-Chicago Melanoma Meeting 2012
4. OncoSec Establishes Clinical Site for Its Phase II Merkel Cell Carcinoma Trial at University of California San Francisco (UCSF)
5. OncoSec OMS ElectroChemotherapy for Head and Neck Cancer Shows Enhanced Quality of Life in Two Randomized Phase III Studies
6. OncoSec Featured on KTVU-TV News and in San Francisco Chronicle
7. OncoSec to Present at the Rodman & Renshaw 2012 Annual Global Investment Conference
8. OncoSec Granted New Patent from China
9. OncoSec to Present at Upcoming Healthcare and Investor Conferences
10. OncoSec Medical Reports Positive Interim Efficacy Results from Phase IV Study of NeoPulse in Skin Cancer Patients
11. OncoSec Medical Reports Positive Preliminary Efficacy Results from Phase II Study of ImmunoPulse in Metastatic Melanoma Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... , Dec. 17, 2014 PCCA received ... ( http://bit.ly/1382OkS ) program seal for best ... The program highlights medical practices, materials and goods ... friendly." Children affected by autism often ... be exacerbated by ingredients found in food and ...
(Date:12/15/2014)... DUBLIN , Dec. 12, 2014 Research ... announced the addition of the "MEMS Gyroscopes ... Costing Analysis" report to their offering. ... MEMS gyroscopes for tactical grade applications made a ... in term of reliability. They are now accepted ...
(Date:12/15/2014)... DUBLIN , Dec. 12, 2014 Research and ... addition of the "Inferior Vena Cava (IVC) Filters ... to their offering. http://photos.prnewswire.com/prnh/20130307/600769 ... sector is projected to reach US$435 million by 2016. ... nearly 39% (2015) of the global value while ...
Breaking Medicine Technology:Parents Of Children With Autism Spectrum Disorder Have New Options When Administering Medications 2Parents Of Children With Autism Spectrum Disorder Have New Options When Administering Medications 3MEMS Gyroscopes Analog Devices ADIS16136 Precision Angular Rate Sensor Reverse Costing Analysis 2Inferior Vena Cava (IVC) Filters - Global Trends, Estimates and Forecasts, 2012-2018 2Inferior Vena Cava (IVC) Filters - Global Trends, Estimates and Forecasts, 2012-2018 3Inferior Vena Cava (IVC) Filters - Global Trends, Estimates and Forecasts, 2012-2018 4
... 04, 2007 /PRNewswire-FirstCall/ --,Bionovo, Inc.'s lead drug ... the treatment of hot flashes associated with ... in the company's,double-blind, placebo- controlled, randomized Phase ... moderate to severe hot flashes,per week were ...
... analyses of progression-free survival in,the SPARC Phase ... risk of disease progression for patients receiving,satraplatin. ... well as presence or absence of pain., ... and GPC Biotech AG today announced the ...
Cached Medicine Technology:Bionovo's MF101 Shows Positive Safety, Tolerability and Efficacy in,Phase 2 Trial 2Bionovo's MF101 Shows Positive Safety, Tolerability and Efficacy in,Phase 2 Trial 3Bionovo's MF101 Shows Positive Safety, Tolerability and Efficacy in,Phase 2 Trial 4Bionovo's MF101 Shows Positive Safety, Tolerability and Efficacy in,Phase 2 Trial 5Additional New Data from Satraplatin SPARC Phase 3 Investigational,Trial Presented at ASCO Annual Meeting 2Additional New Data from Satraplatin SPARC Phase 3 Investigational,Trial Presented at ASCO Annual Meeting 3Additional New Data from Satraplatin SPARC Phase 3 Investigational,Trial Presented at ASCO Annual Meeting 4Additional New Data from Satraplatin SPARC Phase 3 Investigational,Trial Presented at ASCO Annual Meeting 5Additional New Data from Satraplatin SPARC Phase 3 Investigational,Trial Presented at ASCO Annual Meeting 6Additional New Data from Satraplatin SPARC Phase 3 Investigational,Trial Presented at ASCO Annual Meeting 7
(Date:12/19/2014)... NJ (PRWEB) December 19, 2014 ... Inside Patient Care: Pharmacy & Clinics™, an independent ... healthcare team treating and caring for patients inside ... primary care expands to provide optimal access to ... offers a forum for the team treating and ...
(Date:12/19/2014)... (PRWEB) December 19, 2014 ... the diagnostic, personalized medicine, healthcare information technology, and ... the position of Chief Operating Officer. The announcement ... Partners, marked by a strengthened presence in Boston ... , "Leslie lives and breathes the client experience," ...
(Date:12/19/2014)... (HealthDay News) -- Being in good shape seems to reduce ... looked at data from more than 57,000 Americans, including more ... between 1991 and 2009. Those in the poorest shape ... blood pressure at the start of the study, compared to ... fitness. Of the more than 8,000 people diagnosed with ...
(Date:12/19/2014)... Traveling through the same U.S. airport gate, one infected ... a four-hour time span, illustrating just how easily the ... exposures in this report were not prolonged and occurred ... the fact that measles is highly contagious," wrote a ... at the U.S. Centers for Disease Control and Prevention. ...
(Date:12/17/2014)... 2014 Unidesk Corporation today announced ... which welcomed its inaugural class in August 2013, ... seamlessly support bring your own device (BYOD) and ... experience. The solution, comprised of Citrix XenDesktop ... server and storage infrastructure and Unidesk ...
Breaking Medicine News(10 mins):Health News:The Transformation of Retail Pharmacies into a Healthcare Delivery Center 2Health News:The Transformation of Retail Pharmacies into a Healthcare Delivery Center 3Health News:Slone Partners Promotes Leslie Loveless to Chief Operating Officer 2Health News:Being Fit Keeps Blood Pressure in Check 2Health News:Arriving Now at Gate 42: Measles 2Health News:Arriving Now at Gate 42: Measles 3Health News:Alabama College of Osteopathic Medicine Deploys Desktop Virtualization Solution from Citrix, Dell and Unidesk 2Health News:Alabama College of Osteopathic Medicine Deploys Desktop Virtualization Solution from Citrix, Dell and Unidesk 3
... Health Reform, Progressives Hail Choice of HHS Secretary and White ... America,s Future co-director Roger Hickey congratulated President ... Sebelius , D-Kansas, to be secretary of health and human ... of the White House Office for health Reform. Hickey praised ...
... Corporation (NYSE: HLS ) today announced it ... on March 10-11, 2009, at the Loews Miami Beach ... Officer Jay Grinney and Executive Vice President and Chief ... March 10, at 9:30 a.m. EDT. The presentation will ...
... seems to play a role, study finds, , , MONDAY, ... increases the risk of suicide in young adults, says ... for 15 years after they started first grade in ... the participants when they were young adults (average age ...
... InjunctionWASHINGTON, March 2 The United States has ... its subsidiaries, ETHEX Corp. and Ther-Rx Corp., and ... and unapproved drugs, the Justice Department announced today. ... injunction in a consent decree. The FDA conducted ...
... 2 /PRNewswire-Asia-FirstCall/ -- China Nepstar,Chain Drugstore Ltd. (NYSE: ... drugstore chain in China based on the number of ... the fourth quarter and,fiscal year 2008 financial results ended ... 16, 2009. , The Company ...
... warn parents that instruction alone is no guarantee , , ... in swimming lessons doesn,t increase their risk of drowning, ... health professionals that swimming lessons could actually increase drowning ... youngsters are in and around water. , U.S. ...
Cached Medicine News:Health News:Praise for Sebelius, DeParle From Campaign for America's Future Co-Director Roger Hickey 2Health News:Post-Traumatic Stress Tied to Increased Suicide Risk 2Health News:United States Files Suit Against Missouri-Based Pharmaceutical to Block Manufacturing and Shipping of Unapproved Drugs 2Health News:China Nepstar Chain Drugstore to Announce Fourth Quarter and Fiscal 2008 Financial Results on March 16 2Health News:Swimming Lessons Don't Increase Drowning Risk, Study Says 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: